Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2008;39:1022-1024
Published online before print January 31, 2008, doi: 10.1161/STROKEAHA.107.495754
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/3/1022    most recent
STROKEAHA.107.495754v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Denes, L.
Right arrow Articles by Nagy, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Denes, L.
Right arrow Articles by Nagy, Z.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Restenosis
Right arrow Smooth muscle proliferation and differentiation
Right arrow Other Stroke
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology

(Stroke. 2008;39:1022.)
© 2008 American Heart Association, Inc.


Research Letters

Reverse Regulation of Endothelial Cells and Myointimal Hyperplasia on Cell Proliferation by a Heatshock Protein-Coinducer After Hypoxia

Laszlo Denes, PhD; Zoltan Bori, MS; Eva Csonka, DSc; Laszlo Entz, MD, PhD Zoltan Nagy, MD, DSc

From the National Stroke Centre (L.D., Z.B., E.C., Z.N.), National Institute of Psychiatry and Neurology, Section of Vascular Neurology; Department of Vascular Surgery (L.E.), Semmelweis University, Budapest, Hungary.

Correspondence to Laszlo Denes, PhD, National Stroke Centre, National Institute of Psychiatry and Neurology, H 1021 Budapest, Hüvösvölgyi str. 116, Hungary. E-mail dr.denes{at}gmail.com


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background and Purpose— Myointimal hyperplasia (MIH) cells are related to permanent upregulated proliferation as tumor-like cells. The aim of this study is to assess whether treatment of cells after hypoxia by Iroxanadine heat-shock protein (HSP-coinducer) predicts recovery through cell proliferation.

Methods— Vascular smooth muscle cells (VSMC) and brain capillary endothelial cells (HBEC) were isolated from human origin and MIH-cells from early carotid restenosis after surgery. Cell proliferation was quantified by bromuridine (BrdU) incorporation after hypoxia/reoxygenation. HSP72 and cyclin-dependent kinase (CDKN1A) mRNA expression was assessed by reverse transcription-polymerase chain reaction (PCR) and cell cycle distribution by flow cytometry (FACS) analysis.

Results— After hypoxia/reoxygenation, the proliferation of MIH-cells increased, whereas endothelial cells decreased (MIH: 0.266±0.016 versus 0.336±0.024; P<0.05; HBEC: 1.249±0.10 versus 0.878±0.11; P<0.05). Whereas augmented proliferation of MIH-cells was reduced (40% to 45%) by HSP-coinducer, diminished HBEC proliferation increased (46.2%). Stress-activated-protein-kinase (SAPK)p38-dependent cell cycle redistribution was generated by an increase in HSP72 and CDKN1A mRNA levels in MIH-cells.

Conclusions— The 2 key players of early restenosis (MIH, EC) were oppositely regulated and correspondingly after treatment by HSP-coinducer reverse recovered. Drug candidate may have therapeutic potential in (re)restenosis.


Key Words: carotid stenosis • endothelium • heatshock-protein • proliferation • smooth muscle cells


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Early restenosis (6 to 12 months after intervention) resulting from myointimal hyperplasia (MIH) is related to upstream proliferation of SMCs and down-regulated endothelial function that may be related to clinical symptoms. Therefore, strategies have been proposed to prevent early restenosis by agents and newly carotid artery stenting. Recently, drug-eluting stents is an alternative therapy still with problems.

Iroxanadine (Cytrx; 5, 6-dihydro-5- (1-piperidinyl) methyl-3- (3-pyridil)-4H-1, 2, 4-oxadiazine), originally synthesized by Biorex-Hungary (BRX-235), is a drug candidate with a marked cytoprotection by heatshock protein (HSP)-coinduction.1 This molecule has been proposed to stimulate the migration of ECs via p38 stress-activated-protein-kinase (SAPK) and enhanced expression of HSPs and heat-shock transcription factor 1.1 However, no data were published according to this HSP-coinducer focusing on the effect regarding MIH.

We will show how BRX-235 interferes with MIH, human brain endothelial cells (HBEC) and vascular smooth muscle cells (VSMC) under hypoxia/reoxigenation.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The following cells were isolated from human origin: VSMCs/carotid wall2; brain capillary endothelial cells (HBEC)/cut of brain gray matter3 from accidental cadaver donors, and MIH-cells/segment of operated artery.

Cultivated cells were exposed to hypoxia (for 1 hour) in Billups-Rothenberg chamber and reoxygenated for overnight. Before hypoxia the endothelial cells were starved overnight by serum deprivation (1%).

MIH cells were isolated and cultured from surgical speciments of early restenosis. The 7 patients (age 62 to 78) were operated (6 to 12 months) after the first endarteriectomy, whereas the second interventions were patch plastic, or interposition. No patients were lost and no neurological events occurred because of surgery.

Permission to isolate cells of human origin was granted by the Ethical Committee of the Hungarian Ministry of Health (595/98/KO and 73/1998/ETT). Materials were obtained primarily from Sigma.

Cell cultures were treated with HSP-coinducer (10–8-10–7-10–6 mol/L) next exposed to bromuridine (bromuridine [BrdU]/Roche Diagnostics Kit) overnight, the amount of incorporated BrdU measured by ELISA-reader. Cell cycles of MIH-cells were measured by flow cytometry (fluorescence activated cell sorter [FACS] Calibur).

Total cellular RNA was prepared and reverse transcription performed, the cDNA synthesized, 28S rRNA (forward and reverse Acc. No.: U13369), amplified cyclin dependent kinase (CDKN1A)/WAF-1 (forward and reverse Acc. No.: L25610) and HSP72 cDNA (forward and reverse Acc. No.: L12723) specific primer pairs were designed. The amplified reverse transcription-polymerase chain reaction (PCR) products were visualized and demonstrated on figure.

Statistical analyses were performed by 1-way ANOVA and significance calculated by Student t test.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
The proliferation rate of nonpathological cells: VSMC (n=4) and HBECs (n=6) decreased (21.2%, P=0.049, and 30.7%, P=0.009) after hypoxia/reoxygenation. Conversely, the activity of cultured MIH (n=7) cells increased (31.4%, P=0.001; Figure 1a). Using HSP-coinducer at normoxia, the upregulated proliferation rate of MIH-cells reduced (22.8±1.1 P=0.048) similarly after hypoxia/reoxygenation (0.1 µmol/L to 1 µmol/L Iroxanadine 37.1±2.5% P=0.007, 34.3±3.0% P=0.009; Figure 1b). Contrarily, the downstreamed proliferation rate of HBECs was upregulated while the test drug did not elicit any effect on VSMC (Figure 1c).


Figure 1495754
View larger version (19K):
[in this window]
[in a new window]

 
Figure 1. Proliferation of HBEC, VSMC and MIH-cells by incorporated BrdU. Proliferation (after 1 h hypoxia, 24 h reoxygenation) was measured by ELISA, calculated (mean±SEM). Difference of significance are *P<0.05, **P<0.01 and ***P<0.005 by Student t test. a, Proliferation rations of 3 cells are compared on normoxia (dark bars); on hypoxia (open bars) and Hypox=Hypoxia; SD=Serum Deprivation; b, treated MIH cell proliferation on normoxia and on hypoxia/reoxygenation. Control cells (dark bars), treated by HSP-coinducer: 0.1 µmol/L (open lines), 1.0 µmol/L (ruled bars) and 10 µmol/L (dotted bars); c, proliferation of HBEC and control VSMC after hypoxia/reoxygenation are depicted at normoxia (dark bars) and after hypoxia/reoxygenation (open bars). The HSP-coinducer treatment is demonstrated as shown above.

In MIH cell population the subpopulation of G0/G1 phase cells represented the highest percentage, but no change was observed after HSP-coinduction. The number of S phases of cells downstreamed (17.8±0.7/12.3±1.0%; P=0.008) and G2/M increased (10.2±1.1/17.0±0.9%; P=0.0078; Figure 2a, b). An opposite effect appeared by SAPKp38 inhibitor (SB203580 1 µmol/L). The number of S phase cells increased (17.0±0.9 /21.2±1.0%; P=0.046) except for G2/M subpopulation (8.2±0.8 /9.8±1.0%; Figure 2a). The HSP-coinducer (1 µmol/L) counteracted the effect of SB203580 (1 µmol/L) and increased the cell ratio of G2/M phase and decreased the upregulated cell ratio of S phase (Figure 2b). Thus, the HSP-coinducer induced p38-dependent cell cycle redistribution on cell subpopulations.


Figure 2495754
View larger version (11K):
[in this window]
[in a new window]

 
Figure 2. Cell cycle of MIH-cells with HSP-coinducer and SB203580 tested by FACS. a, Percentage of G2/M and S cells after HSP-coinducer or SB203580 treatment. b, G2/M and S cells after HSP-coinducer and SB203580.

In VSMC after hypoxia/reoxygenation, HSP72 and CDKN1A mRNA levels did not change (data not depicted). In HBEC treated with HSP-coinducer (for 5 days) after hypoxia/reoxigenation both the HSP72 mRNA (4.9-fold) and the CDKN1A mRNA (4.7-fold) decreased. In MIH a slight upregulation of HSP72 (2.6- to 3.0-fold) and CDKN1A mRNA level (1.5- to 1.9-fold) was measured. The HSP-coinducer treatment reversed the effect of hypoxia/reoxygenation (Figure 3).


Figure 3495754
View larger version (25K):
[in this window]
[in a new window]

 
Figure 3. HSP72 and CDKN1A mRNA expression on MIH and HBEC after HSP-coinduction. PCR were performed in 3 parallel tubes of the same cDNA samples. Lanes: 2 µL of cDNA from cells without HSP-coinducer 1 to 3 (EC) and 7 to 9 lines (MIH); Treated cells: 4 to 6 (EC) and 10 to 12 (MIH); 13 line: 2 µL negative control of cDNA (NC).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
A definitive therapy on restenosis and in-stent stenosis, especially targeting VSMC as well as endothelial cell dysfunction, is warranted.4

Cultured MIH-cells with hypoxia/reoxygenation are used as model of restenosis to test drug actions. In between MIH-cells and endothelial cells reverse regulation was observed on cell proliferation particularly after hypoxia. The proliferation of nonpathological cells (VSMC and EC) decreased while pathological MIH-cells greatly increased. This novel observation explains different mechanisms in early restenosis.

Drug-induced HSPs may have therapeutic effects under different pathological conditions.1 After treatment by HSP-coinducer, the augmented proliferation of MIH-cells decreased but the proliferation of deregulated EC cells was enhanced. Simultaneously, the expression of HSP72 and CDKN1A are upregulated in agreement with clinical reports where compromised endothelial cell proliferation and upregulated HSP72 expression was described in VSMC after transluminal balloon angioplasty.5

MIH-cells are characterized by augmented proliferation, similar to tumor cells. Induced by heat or stress proteins, tumor suppressor p53 inhibited cell growth by enhanced expression of CDKN1A/p21.6 While not in HBEC and VSMCs, CDKN1A/p21 upregulation was documented in the MIH cell culture after HSP-induction.

As we documented, MIH and endothelial cells, the 2 key players of early restenosis, were oppositely regulated. Iroxanadine, a HSP-coinducer, may prevent restenosis by its regulatory action.


*    Acknowledgments
 
Sources of Funding

The study was supported by grants from the Hungarian National Science Foundation OTKA 2001 T-037887; Scientific Council of Ministry of Health (ETT 096/2003) and Agreement with Biorex Research and Development Co (K 276/2002) and with permission of Cytrx Co.

Disclosures

None.

Received June 13, 2007; revision received July 28, 2007; accepted August 1, 2007.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Soti Cs, Nagy E, Giricz Z, Vígh L, Csermely P, Ferdinandy P. Heat-shock proteins as emerging therapeutic targets. Brith J Pharmacol. 2005; 146: 769–780.[CrossRef]

2. Csonka E, Szemenyei K, Miskulin M, Robert AM. Morphological examination of aortic endothelial and smooth muscle cells grown in vitro on collagen membranes. Artery. 1980; 8: 253–258.[Medline] [Order article via Infotrieve]

3. Nagy Z, Kolev K, Csonka É, Pék M, Machovich R. Contraction of human brain endothelial cells induced by thrombogenic and fibrinolitic factors. Stroke. 1995; 26: 265–270.[Abstract/Free Full Text]

4. Gröschel K, Riecker A, Schulz JB, Ernemann U, Kastrup A. Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke. 2005; 36: 367–373.[Abstract/Free Full Text]

5. Kirby LB, Mondy JS, Broophy CM. Balloon angioplasty induces heat-shock protein 70 in human blood vessels. Ann Vasc Surgery. 1999; 13: 475–479.[CrossRef]

6. Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y, Komori K, Sugimachi K. Sueishi K. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res. 1998; 82: 147–156.[Abstract/Free Full Text]





This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/3/1022    most recent
STROKEAHA.107.495754v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Denes, L.
Right arrow Articles by Nagy, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Denes, L.
Right arrow Articles by Nagy, Z.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Restenosis
Right arrow Smooth muscle proliferation and differentiation
Right arrow Other Stroke
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology